Postprogression Survival in Patients With Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the treatment outcome in patients with NSCLC or colorectal cancer similar to patients in our study is generally poor.”
From KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Lee, D. H., Park, K., Kim, J. H., Lee, J.-S., Shin, S. W., Kang, J.-H., Ahn, M.-J., Ahn, J. S., Suh, C., & Kim, S.-W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1903 · Cited by 179
Pallis, A. G., Agelaki, S., Agelidou, A., Varthalitis, I., Syrigos, K., Kentepozidis, N., Pavlakou, G., Kotsakis, A., Kontopodis, E., & Georgoulias, V. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-633 · Cited by 36
Research works printed but not linked: 19
- Breathnach, 2001, Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results, J Clin Oncol, 19, 1734, 10.1200/JCO.2001.19.6.1734 · DOI · Paper page
- Carney, 2002, Lung cancer—time to move on from chemotherapy, N Engl J Med, 346, 126, 10.1056/NEJM200201103460211 · DOI · Paper page
- Hotta, 2007, Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer, J Thorac Oncol, 2, 96, 10.1097/JTO.0b013e31802bb010 · DOI
- Hotta, 2004, Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer, J Clin Oncol, 22, 3852, 10.1200/JCO.2004.02.109 · DOI · Paper page
- Wakelee, 2006, Changes in the natural history of nonsmall cell lung cancer (NSCLC)—comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990, Cancer, 106, 2208, 10.1002/cncr.21869 · DOI
- Soria, 2010, Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?, Ann Oncol, 21, 2324, 10.1093/annonc/mdq204 · DOI
- Hayashi, 2012, Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer, Ann Oncol, 23, 1537, 10.1093/annonc/mdr487 · DOI
- Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354 · DOI · Paper page
- Kim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016/S0140-6736(08)61758-4 · DOI · Paper page
- Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 · DOI · Paper page
- Saad, 2010, Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials, J Clin Oncol, 28, 1958, 10.1200/JCO.2009.25.5414 · DOI · Paper page
- DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
- Johnson, 2006, Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis, Lancet Oncol, 7, 741, 10.1016/S1470-2045(06)70800-2 · DOI · Paper page
- Sculier, 2008, The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition, J Thorac Oncol, 3, 457, 10.1097/JTO.0b013e31816de2b8 · DOI · Paper page
- Brundage, 2002, Prognostic factors in non-small cell lung cancer: a decade of progress, Chest, 122, 1037, 10.1378/chest.122.3.1037 · DOI · Paper page
- Broglio, 2009, Detecting an overall survival benefit that is derived from progression-free survival, J Natl Cancer Inst, 101, 1642, 10.1093/jnci/djp369 · DOI · Paper page
- Ramlau, 2006, Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer, J Clin Oncol, 24, 2800, 10.1200/JCO.2005.03.6491 · DOI
- Herbst, 2010, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial, Lancet Oncol, 11, 619, 10.1016/S1470-2045(10)70132-7 · DOI · Paper page
- Takeda, 2009, Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104), Ann Oncol, 20, 835, 10.1093/annonc/mdn705 · DOI
Cited by
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Prasad, V., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 403
Metadata
- Authors
- Hayashi, H., Okamoto, I., Taguri, M., Morita, S., & Nakagawa, K.
- Venue
- Clinical Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 14
- Issue
- 3
- Pages
- 261-266
- ISSN
- 1525-7304
- Cited by
- 35
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Postprogression Survival in Patients With Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy. https://app.cochat.ai/papers/10.1016/j.cllc.2012.09.006
- The paper
- Hayashi, H., Okamoto, I., Taguri, M., Morita, S., & Nakagawa, K. (2013). Postprogression Survival in Patients With Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2012.09.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.